Rocket Pharmaceuticals Announces Participation at Upcoming Conferences


Rocket Pharmaceuticals, Inc. (Nasdaq:RCKT) (Rocket), a leading U.S.-based multi-platform gene therapy company, today announces participation at the following upcoming industry conferences:

  • Cowen and Company 39th Annual Health Care Conference
    • Kinnari Patel, Pharm.D., MBA, COO, Jonathan Schwartz, M.D., CMO, and Claudine Prowse, Ph.D., SVP, Strategy, and IRO will participate in a fireside chat on Tuesday, March 12, 2019, at 10:40 a.m. Eastern Time.
  • Alliance for Regenerative Medicine Cell & Gene Investor Day
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Thursday, March 21, 2019, at 9:55 a.m. Eastern Time.
  • American College of Cardiology 2019 Annual Meeting
    • Three abstracts from the Danon disease program have been selected for poster sessions at ACC19, which is being held March 16-18, 2019 in New Orleans, LA. Further information is available in the meetings official planner available here.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (Rocket) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rockets multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Rockets additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for a devastating, pediatric heart failure indication, Danon disease. For more information about Rocket, please visit

Claudine Prowse, Ph.D.
SVP, Strategy, Corporate Development and IRO
Pharma, Inc.
The Empire State Building, Suite 7530
New York,
NY 10118
[email protected]